CN1757402A - Application of Ji-gan-san extractive total flavonoid for preparing medicine to treat ophthalmologic diseases - Google Patents
Application of Ji-gan-san extractive total flavonoid for preparing medicine to treat ophthalmologic diseases Download PDFInfo
- Publication number
- CN1757402A CN1757402A CN 200510106262 CN200510106262A CN1757402A CN 1757402 A CN1757402 A CN 1757402A CN 200510106262 CN200510106262 CN 200510106262 CN 200510106262 A CN200510106262 A CN 200510106262A CN 1757402 A CN1757402 A CN 1757402A
- Authority
- CN
- China
- Prior art keywords
- application
- gan
- san
- group
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
An application of the general flavone extracted from secundspike elsholtzia herb in preparing the medicines for treating the ophthalmopathy caused by diabetes and hypertension, such as eyeground hemorrhage, keratitis, conjunctivitis, etc, the climacteric syndrome, osteporosis, neuro retrograde diseases, cough, etc is disclosed.
Description
Technical field
The present invention relates to medical technical field, the application of Herba Elsholtziae Blandae extract total flavones in the anti-ophthalmic diseases medicine of preparation specifically.
Background technology
Herba Elsholtziae Blandae is the plant Elsholtzia among the people blanda Benth. of Yunnan Province Hani, carries according to " Chinese medicine voluminous dictionary ", has heat clearing away, antiinflammatory, analgesic effect.Usefulness among the people is fried in shallow oil soup and is taken, and is used for the treatment of pyelonephritis, nephritis, flu, hepatitis, dysentery, enteritis, toothache, conjunctivitis, wound hemorrhage, but does not see the information of relevant this drug development research up to now.
Summary of the invention
The purpose of this invention is to provide the application of a kind of Herba Elsholtziae Blandae extract total flavones in the anti-ophthalmic diseases medicine of preparation, the retinal hemorrhage that this medicine causes diabetes, hypertension, keratitis, conjunctivitis, iritis, nyctalopia etc. have better action.
The present invention is the medicine for preparing a kind of anti-ophthalmic diseases with the Herba Elsholtziae Blandae extract total flavones, also is the application of Herba Elsholtziae Blandae extract total flavones in the anti-ophthalmic diseases medicine of preparation.It is retinal hemorrhage, keratitis, conjunctivitis, iritis, the nyctalopia that diabetes, hypertension cause for described ophthalmic diseases.
Medicine of the present invention is to extract extractive of general flavone from the medicinal plants Herba Elsholtziae Blandae, and in extractive of general flavone: adjuvant=60～99: 40～1 ratio is made medicament.
Above-described medicament is the dosage form that is comprised on the pharmaceutics, is specially capsule, granule, tablet and injection etc.
Medicine of the present invention is that the Herba Elsholtziae Blandae plant is is further researched and developed, extracted the effective site in the Herba Elsholtziae Blandae---total flavones, and found that it has therapeutical effect preferably to ophthalmic diseases, in addition, also have class estrogen and pregnancy hormone like-effect, be used for climacteric syndrome, osteoporosis, neurodegenerative diseases and have effects such as eliminating phlegm and stopping cough, anti-capillary fragility and unusual permeability, inhibition tumor cell, spasmolytic, follicle hormone-like function, removing free radical.
Below curative effect of medication of the present invention is described with pharmacodynamic experiment of the present invention.
The present invention is an example with anti-rabbit angle, conjunctivitis test:
Select 30 of Chinese white rabbits for use, be divided into five groups at random, be respectively blank group, model group, ligustrazine group, Kang Ming small dose group, the heavy dose of group of Kang Ming.The ligustrazine group is with 10mg/Kg iv, and Kang Ming small dose group, heavy dose of group be respectively with 50 and 100 μ g/kg ig, blank group and model group with etc. the 0.8%CMC-Na ig of capacity, one day 1 time, successive administration 19 days.Wherein after the administration in the 2nd day, four groups of rabbit right in general back eyelid now pull into cup-shaped, splash into dehydrated alcohol in the eye conjunctival sac with microscale sampler, cause angle, conjunctivitis model with this, and left eye compares.Day by day a record eye conjunctiva, keratopathy were tested the 20th day, put to death animal, got a conjunctiva, cornea tissue is made pathology and observed.
The experimental rabbits general state is observed, no significant difference before and after the modeling.After the rabbit right eye splashes into the dehydrated alcohol modeling, conjunctival congestion, edema, close that order photophobia, secretions increase, the corneal opacity, utmost point significant difference (through the check of grade preface value method, p＜0.001) is relatively arranged with the blank group.After treatment, model control group and blank group relatively have significant difference (p＜0.01); Kang Ming heavy dose of group rabbit conjunctival congestion and blepharoedema and model group relatively have significant difference (p＜0.05). the results are shown in following table 1.
Table 1. Kang Ming extractum is to the influence (n=6) of rabbit angle, conjunctivitis model
| Group | Number of animals (only) | Dosage (μ g/kg) | Conjunctival congestion | Blepharoedema | Secretions | The corneal opacity | Corneal pannus | |||||||||||||||
| - | + | ++ | +++ | - | + | ++ | +++ | - | + | ++ | +++ | - | + | ++ | +++ | - | + | ++ | +++ | |||
| The heavy dose of group of the positive group of blank group model group small dose group | 8 7 8 6 6 | 0.01 50 100 | 8 1 2 1 4 | 0 4 6 5 2 | 0 2 0 0 0 | 0 0 ΔΔ 0 0 0 * | 8 2 2 1 4 | 0 3 5 5 2 | 0 2 1 0 0 | 0 0 ΔΔ 0 0 0 * | 8 2 2 1 3 | 0 3 2 3 3 | 0 2 4 2 0 | 0 0 ΔΔ0 0 0 | 8 1 2 1 3 | 0 3 3 1 1 | 0 1 3 4 2 | 0 2 ΔΔ0 0 0 | 8 2 2 1 4 | 0 1 3 1 1 | 0 1 0 1 0 | 0 3 ΔΔ 3 3 1 |
Annotate: the check of grade preface value, compare with the blank group,
The Δ ΔP＜0.01: compare with model group,
*P＜0.05.
Conjunctival congestion :-: do not have congested; +: mild hyperaemia; ++: obviously congested, be peony; The hyperemia of +++: diffusivity is aubergine.
Eyelid hyperemia :-: no edema; +: Mild edema; ++: obvious edema, part ectropion of lid; +++: be edema obviously, the eyelid semi-closure.
Secretions :-: no abnormal secretions; +: a small amount of secretions; ++: secretions makes eyelid and eyelashes are moist or adhesion; +++: secretions makes the moist or adhesion in whole eye district.
The corneal opacity :-: do not have muddy; +: be dispersed in or the diffusivity muddiness, iris is as seen; ++: greyish white translucent areas occurs, iris is smudgy; +++: is obviously muddy, and iris is unable to recognize.
Corneal pannus :-: do not have; +: 1/4 cornea of growing into; ++: 1/2 cornea of growing into; +++: the 3/4 above cornea of growing into.
Conclusion
The eye local inflammation of the angle that Kang Ming extractum 100 μ g/kg cause dehydrated alcohol, conjunctivitis model rabbit has a better role.
Description of drawings
Fig. 1 extracts the process chart of extractive of general flavone from the Herba Elsholtziae Blandae plant for the present invention.
Fig. 2 is a capsule preparation technology flow chart of the present invention.
The specific embodiment
Embodiment 1: get 500 kilograms of plant Herba Elsholtziae Blandae, after cleaning, extract total flavones by technological process shown in Figure 1, this extracting method has used the technology of using always on the pharmaceutics.
Embodiment 2: with extractive of general flavone and the adjuvant hydroxypropyl cellulose of implementing 1 gained, in extractive of general flavone: the ratio of adjuvant=99: 1, make the capsule of medicine of the present invention by technological process shown in Figure 2, this preparation technology has adopted technology commonly used on the pharmaceutics.
Embodiment 3: with extractive of general flavone and the adjuvant hydroxypropyl cellulose of implementing 1 gained, in extractive of general flavone: the ratio of adjuvant=65: 35, make the capsule of medicine of the present invention by technological process shown in Figure 2, this preparation technology has adopted technology commonly used on the pharmaceutics.
The technological process explanation
Be following several extracting mode in the technological process shown in Figure 1:
Scheme one:
Get the clean medical material of Herba Elsholtziae Blandae, it is an amount of to add water, distillation, and it is standby to collect volatile oil.
Scheme two:
Get the clean medical material of Herba Elsholtziae Blandae, after an amount of industrial alcohol or wetted with methanol, the dress percolator adds solvent and carries out percolation, collects percolate, reclaims to concentrate, and drying under reduced pressure gets dry extract, and pulverizes the back and mixes with adjuvant, granulates, and encapsulated, blister package, outer package are promptly.
Scheme three:
Get the clean medical material of Herba Elsholtziae Blandae, it is an amount of to add water, decocts, and filters, and concentrates the back with the alcohol precipitation, gets supernatant, reclaims to concentrate, and drying under reduced pressure gets dry extract, and pulverizes the back and mixes with adjuvant, granulates, and encapsulated, blister package, outer package are promptly.
Scheme four:
Get the clean medical material of Herba Elsholtziae Blandae, processing industry ethanol or methanol are an amount of, and reflux, extract, reclaims concentrated back and uses water precipitation, gets supernatant, reclaim to concentrate, and drying under reduced pressure gets dry extract, and mixes with adjuvant after pulverizing, and granulates, and encapsulated, blister package, outer package are promptly.
Above-mentioned four kinds of schemes can be carried out simultaneously, also can carry out separately.
Claims (1)
1, the application of Herba Elsholtziae Blandae extract total flavones in the anti-ophthalmic diseases medicine of preparation, it is retinal hemorrhage, keratitis, conjunctivitis, iritis, the nyctalopia that diabetes, hypertension cause for described ophthalmic diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510106262 CN1757402A (en) | 2002-09-13 | 2002-09-13 | Application of Ji-gan-san extractive total flavonoid for preparing medicine to treat ophthalmologic diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510106262 CN1757402A (en) | 2002-09-13 | 2002-09-13 | Application of Ji-gan-san extractive total flavonoid for preparing medicine to treat ophthalmologic diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02133759 Division CN1241563C (en) | 2002-09-13 | 2002-09-13 | Medicine for curing angiocardiopathy and specialty of ophthalmology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1757402A true CN1757402A (en) | 2006-04-12 |
Family
ID=36703071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510106262 Pending CN1757402A (en) | 2002-09-13 | 2002-09-13 | Application of Ji-gan-san extractive total flavonoid for preparing medicine to treat ophthalmologic diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1757402A (en) |
-
2002
- 2002-09-13 CN CN 200510106262 patent/CN1757402A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112716989B (en) | Celery seed extract and preparation method and application thereof | |
| CN103816296B (en) | Callicarpa total glycoside extract and preparation method and application thereof | |
| CN100534508C (en) | Method for extracting effective sites group of smilax China root | |
| CN111053818A (en) | Health care product for adjuvant treatment of skin itch and preparation method thereof | |
| CN107158012A (en) | Application of the Morinda officinalis FOS extract in preventing and treating Alzheimer disease drug, health products or food is prepared | |
| CN1069542C (en) | Medicine for treating chronic hepatism and its preparing process | |
| CN1876051A (en) | Chinese medicinal preparation for treating gynecological disease, its preparation process and quality control method | |
| CN1757402A (en) | Application of Ji-gan-san extractive total flavonoid for preparing medicine to treat ophthalmologic diseases | |
| CN103006781B (en) | Compound Dai medicine extract with liver-protecting effect and preparation method thereof | |
| CN1305866C (en) | Method of extracting phenolic components from chinese medicine red sage root and its freeze dried powder injection agent | |
| CN101274013A (en) | Prescription medicine for curing senile dementia and preparation | |
| CN1552363A (en) | Pungent rhinitis pills and their preparation | |
| CN102861278B (en) | Lipid-lowering extract from effective parts of sharpleaf galangal fruit and preparation and application thereof | |
| CN100343266C (en) | Picrorhiza total glycoside extract and its application in preparation of liver disease medicine and preparation method | |
| CN1887309B (en) | Extraction of effective red sage components for preventing and treating osteoporosis and depression | |
| CN1742926A (en) | Zuoci preparation for deaf and new preparing method thereof | |
| CN1899574A (en) | Chinese medicine composition for preventing and controlling liver cancer and its use | |
| CN1456236A (en) | Preparation of woman effervescent tablets | |
| CN1169873A (en) | Medicine for skin diseases and preparation thereof | |
| CN1456284A (en) | Preparation of ginseng and schisandra fruit capsules | |
| KR100552991B1 (en) | Extraction and Purification of Active Active Ingredients from Jinkyo and Herbal Medicine Compositions Containing the Extracts | |
| CN1456237A (en) | Preparation of instant woman medicine | |
| CN102349926A (en) | New medical application of combination of paeonol, derivative thereof and paeoniflorin | |
| CN1456268A (en) | Preparation of capsules against rhinitis | |
| Bigoniya et al. | Hepatoprotective activity of luteolin from A. millefolium in CCl4 intoxicated rat model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |